Question explored with the scientific record
In the Annals of Internal Medicine long COVID trial, did fluvoxamine or metformin reduce fatigue, and what happened when the metformin dose was cut?
The retrieval surfaced nothing from that Annals trial, so I can't tell you its fluvoxamine, metformin, or fatigue results.
The records I have contain no study testing fluvoxamine in long COVID and no metformin long-COVID trial at all. The metformin papers here are all about diabetes, prediabetes, or cancer, not long COVID [4][5][6][7][8][9]. The fatigue papers test vitamin C, L-arginine, osteopathic treatment, and creatine, not either drug you named [1][2][3][10]. Nothing here reports a metformin dose being cut.
What this retrieval cannot see is the specific trial you're asking about. I don't know it, and I won't guess at what it found. Anyone telling you the fatigue result or the dose-reduction effect without the study in hand is reciting, not reporting.
Separately, on the closest matching drug evidence: in cancer patients, metformin's most common side effects were stomach and gut problems including nausea, vomiting, and diarrhea [4]. In prediabetes, about 30 in 100 on metformin reported gut upset versus about 20 in 100 on berberine [7]. That is the tolerated-dose problem in miniature: it is the gut that usually forces a dose cut, not the fatigue.
My call: the question is unanswerable from these records, and I'd want the actual trial paper, its fatigue scores in each arm, and the stated reason for any dose change before believing any account of it. Confidence: not clear.
Sources used 10
-
Feasibility of Vitamin C in the Treatment of Post Viral Fatigue with Focus on Long COVID, Based on a Systematic Review of IV Vitamin C on Fatigue
A feasibility analysis combining a narrative review and a systematic review to assess whether high‑dose intravenous vitamin C could be a viable treatment for post‑viral fatigue, especially long COVID, by summarizing nine clinical studies (720 participants) that generally show fa…
DOI: 10.3390/nu13041154 -
Role of L-Arginine supplementation in Long Covid-related Fatigue and Depression in Elderly Outpatients
A double-blind RCT of 96 elderly outpatients with Long Covid fatigue and depression found that adding L-arginine to SSRI for 8 weeks led to a 30% greater improvement in fatigue and a significant reduction in HAM-D score versus SSRI alone.
DOI: 10.1192/j.eurpsy.2024.257 -
Acute Effects of Osteopathic Treatment in Long COVID-19 Patients with Fatigue Symptoms: A Randomized, Controlled Trial
A single-session randomized, sham-controlled trial in long COVID patients with fatigue showing that osteopathic treatment acutely enhances heart rate variability and parasympathetic indices, with effects that appeared short-lived and did not persist at 48 hours, suggesting trans…
DOI: 10.3390/jcm14176066 -
The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial
In non-diabetic Egyptian women with locally advanced breast cancer, adding metformin to anthracycline/taxane neoadjuvant chemotherapy non-significantly improved pCR, cCR, ORR, and BCR, and was safe and tolerable without affecting quality of life.
DOI: 10.1038/s41598-022-11138-3 -
Comparative Study of Efficacy and Adverse Effects of Metformin Plus Empagliflozin Versus Metformin Plus Sitagliptin in Diabetes Mellitus Type II Patients
Metformin plus empagliflozin yields greater HbA1c reduction and fewer diarrhea and urinary adverse events than metformin plus sitagliptin over 3 months in type 2 diabetes patients, with similar hypoglycemia risk.
DOI: 10.70749/ijbr.v3i7.1254 -
Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus
This nationwide propensity score-matched study found that metformin monotherapy is associated with a lower incidence of major adverse cardiac events (MACEs) among patients with a new diagnosis of type 2 diabetes mellitus compared to those who only underwent lifestyle modificatio…
DOI: 10.1097/MD.0000000000007507 -
Comparative study of efficacy and safety of berberine hydrochloride versus metformin in newly diagnosed prediabetic patients: a randomized clinical trial
Berberine hydrochloride produced glycemic improvements comparable to metformin over 12 weeks in adults with newly diagnosed prediabetes, with a lower incidence of gastrointestinal adverse events.
DOI: 10.18203/2319-2003.ijbcp20252563 -
Targeting hyperglycaemia with either metformin or repaglinide in non‐obese patients with type 2 diabetes: results from a randomized crossover trial
In non-obese Caucasian adults with type 2 diabetes, metformin and repaglinide produced equivalent HbA1c reductions over 4 months in a randomized crossover trial.
DOI: 10.1111/j.1463-1326.2007.00713.x -
Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials
This updated meta-analysis evaluates the effects of metformin on all-cause mortality and major adverse cardiovascular events (MACEs) in patients with type 2 diabetes, finding a significant association with lower risk of MACEs and a tendency towards reduced all-cause mortality co…
DOI: 10.1016/j.numecd.2020.11.031 -
Creatine as a mitochondrial theranostic in predictive, preventive, and personalized medicine
This mini-review advocates creatine as a mitochondria-targeted theranostic within predictive, preventive, and personalized medicine (PPPM), synthesizing mechanistic evidence of mitochondrial support with clinical data showing diagnostic potential and therapeutic benefits in cond…
DOI: 10.1007/s13167-025-00420-9